Skip to main content
Bioasis Technologies Inc. logo

Bioasis Technologies Inc. — Investor Relations & Filings

Ticker · BIOAF LEI · 529900ORRO8R51S5MW75 TSXV Manufacturing
Open in API
Filings indexed 120 across all filing types
Latest filing 2023-06-20 Regulatory Filings
Country CA Canada
Listing TSXV BIOAF

About Bioasis Technologies Inc.

https://www.bioasis.us

Bioasis Technologies Inc. is a development-stage biopharmaceutical company focused on the research and development of proprietary technologies and products for Central Nervous System (CNS) diseases and brain-related disorders. Its core technology is the xB3 platform, a proprietary system designed to facilitate the transport and delivery of therapeutic agents across the challenging blood-brain barrier (BBB). The company's in-house programs aim to develop both symptomatic and disease-modifying treatments, as well as diagnostic technologies, addressing the limitations inherent in treating complex neurological conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a corporate update from Bioasis Technologies Inc. announcing the suspension of operations due to financial difficulties, including inability to pay auditors and anticipated regulatory consequences such as a cease trade order and trading suspension. It discusses strategic alternatives pursued, bridge loans, and a non-binding term sheet for licensing. There are no financial statements, detailed financial data, or comprehensive management discussion and analysis included. The document is a public announcement about the company's operational and financial status rather than a formal financial report or filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory certification or officer attestation. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the company's status and anticipated regulatory actions, which is the fallback category for such disclosures.
2023-06-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the opening of four new retail locations by Ayr Wellness in Florida. It contains forward-looking statements about the company's growth plans and operational details but does not include any financial statements, detailed financial performance data, or regulatory filings. There is no indication that this is an earnings release, annual or interim report, or any other formal financial report. It is a corporate announcement about expansion and operational updates. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate news, which corresponds to Regulatory Filings (RNS). The document length is about 5,147 characters, which is sufficient for a full report but the content is clearly a news announcement rather than a report itself.
2023-03-23 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and contains detailed information about a material change event involving the termination of an arrangement agreement between Bioasis Technologies Inc. and Midatech Pharma plc. It includes a press release as Schedule A, describing the termination of the acquisition agreement due to shareholder vote rejection. The document discusses strategic alternatives, financing, and operational outlook. The form number 51-102F3 and the nature of the content indicate this is a regulatory filing related to a material change event, which is a type of regulatory announcement rather than a full financial report or earnings release. It is not an annual or interim report, audit report, or earnings release. It is also not a proxy, voting result, or management change announcement. The document is a formal regulatory disclosure of a material corporate event, fitting the category of Regulatory Filings (RNS). The document length (7718 characters) and content confirm it is not merely an announcement of a report but a substantive regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2023-02-01 English
News release - English.pdf
M&A Activity Classification · 90% confidence The document is a press release announcing the termination of an arrangement agreement between Bioasis Technologies Inc. and Midatech Pharma plc. It discusses the failure of a shareholder vote to approve the arrangement, the resulting termination of the agreement, and the company's plans to explore other strategic alternatives and financing options. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content focuses on a corporate transaction update and strategic status rather than a merger filing or detailed merger communications. It is not a merger & acquisition filing (MA or TAR) because it announces termination rather than a merger or acquisition event. It is not a capital/financing update (CAP) because it does not announce new financing but mentions financing needs. It is not a regulatory filing (RNS) because it is a substantive announcement about a corporate event. The best fitting category is M&A Activity (TAR) as it relates to the termination of a merger arrangement agreement, which is part of merger and acquisition activity announcements.
2023-01-23 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate. It is a certification by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended November 30, 2022. The document does not contain the actual interim financial statements or substantive financial data but is a certification letter related to the interim filings. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3009 characters, which is relatively short and consistent with a certification letter rather than a full report.
2023-01-19 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CFO of Bioasis Technologies Inc. regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended November 30, 2022. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The document does not contain actual financial statements or substantive financial data but is an officer certification related to interim filings. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is short (3012 characters), and it is clearly a certification letter, not the full interim report.
2023-01-19 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.